IXICO, a global leader in neuroscience imaging and biomarker analytics, has secured full data usage rights to the Bio-Hermes-002 study through a strategic partnership with the Global Alzheimer's Platform Foundation (GAP). The agreement positions IXICO as a key consortium partner alongside leading biopharmaceutical companies in one of the most prominent global studies in Alzheimer's disease research.
Strategic Partnership Details
Under the agreement announced July 22, 2025, IXICO will provide GAP with a combination of cash and analysis services in exchange for comprehensive data usage rights to Bio-Hermes-002. The company will leverage its AI-driven platform and expertise to assist with neuroimaging analysis of the study data, building upon findings from the predecessor Bio-Hermes-001 study.
"This official partnership strengthens the deep collaboration between IXICO and GAP," said Bram Goorden, CEO of IXICO. "Working with GAP and the consortia partners is very rewarding clinically, and it is also particularly important for two strategic reasons. Firstly, it confirms IXICO's leading role in the AD research ecosystem, a key element in driving continued commercial opportunities."
Bio-Hermes-002 Study Objectives
The Bio-Hermes-002 study represents a unique observational platform that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images, and numerous races and ethnicities. The study aims to generate data that may help predict, detect and diagnose Alzheimer's disease and related dementias by gathering information on each biomarker's ability to diagnose and predict the accumulation of amyloid and tau in the brain—hallmark characteristics of Alzheimer's disease.
The research seeks volunteers with or without memory concerns to help identify new blood or digital tests that can predict the presence of amyloid plaques and neurofibrillary tangles in the brain. Bio-Hermes-002 builds on the success of Bio-Hermes-001, which was the first-of-its-kind study comparing blood-based biomarkers, digital cognitive tests, retinal exams, and speech analytics to traditional methods including beta-amyloid positron emission tomography (PET) scans.
Commercial and Research Impact
The board expects a strong return on this investment, as data from Bio-Hermes-002 will enable IXICO to directly accelerate its market differentiating vascular biomarker analysis R&D program in AD and adjacent neurodegenerative diseases. The partnership will also extend IXICO's product offering to support blood-based biomarker market approval and use in AD while deepening its relationship with GAP and enabling direct engagement with leading biopharmaceutical companies in the AD space.
"The unique study data enables us to further develop highly differentiated neuroimaging biomarker technologies that advance the understanding, diagnosis and treatment for patients suffering from AD," Goorden added.
Collaborative Ecosystem
IXICO joins an extensive list of collaborators in Bio-Hermes-002, including major pharmaceutical companies Biogen, Eli Lilly and Company, and Roche. Additional partners providing blood-based biomarker assessments or digital assessments include AINOSTICS, Beckman Coulter Diagnostics, Cambridge Cognition Limited, Cognivue, Cumulus Neuroscience Limited, Fujirebio, iLoF, LifeArc, Linus Health, Lucent Diagnostics (a Quanterix brand), Sunbird Bio, and ViewMind.
John Dwyer, President of GAP, emphasized the collaborative nature of the effort: "Our shared goal is to transform how clinical trials are designed for Alzheimer's and related dementias. By applying cutting-edge technologies to improve the detection of underlying disease pathology, we hope to accelerate meaningful progress for individuals and families affected by these conditions."
Data Accessibility and Future Impact
Data from the Bio-Hermes-002 study will be stored on the AD Workbench from the Alzheimer's Disease Data Initiative (ADDI), a global, secure, cloud-based data sharing and analytics environment. After the study closes, the data will eventually become available to Alzheimer's researchers worldwide as part of the Alzheimer's Disease Discovery Initiative's AD Workbench, potentially accelerating broader research efforts in the field.
The partnership represents a significant step in advancing biomarker research for Alzheimer's disease, with the potential to improve diagnostic capabilities and accelerate the development of new treatments for patients suffering from AD and related dementias.
